Gary Lee Ellis
Known title: DirectorCIK: 0001290170
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
TTC Featured in Dividend Champion, Contender, And Challenger Highlights. The Toro Company was included in a recent list of dividend-focused stocks. This highlights the company's 1.61% dividend yield to investors. The stock is currently trading near its 52-week high, with an average analyst target of $111.00.
Transaction History
| INSP | ▲ Buy | Grant | 581 | $0 | 7/15/2026 | View on chart |
| TTC | ▲ Buy | Option Exercise | 4,951 | $234K | 6/9/2026 | View on chart |
| TTC | ▼ Sell | Open Market | 4,951 | $455K | 6/9/2026 | View on chart |
| INSP | ▲ Buy | Grant | 3,562 | $0 | 4/30/2026 | View on chart |
| INSP | ▲ Buy | Grant | 518 | $27K | 4/15/2026 | View on chart |
| INSP | ▲ Buy | Grant | 304 | $29K | 1/15/2026 | View on chart |
| TTC | ▲ Buy | Grant | 1,235 | $92K | 11/3/2025 | View on chart |
| INSP | ▲ Buy | Grant | 372 | $29K | 10/14/2025 | View on chart |
| INSP | ▲ Buy | Grant | 221 | $28K | 7/15/2025 | View on chart |
| TTC | ▲ Buy | Option Exercise | 5,038 | $190K | 6/11/2025 | View on chart |
| TTC | ▼ Sell | Open Market | 5,038 | $357K | 6/11/2025 | View on chart |
| INSP | ▲ Buy | Grant | 1,266 | $0 | 5/1/2025 | View on chart |
| INSP | ▲ Buy | Grant | 169 | $25K | 4/14/2025 | View on chart |
| INSP | ▲ Buy | Grant | 137 | $24K | 1/15/2025 | View on chart |
| TTC | ▲ Buy | Grant | 1,011 | $82K | 11/1/2024 | View on chart |
| INSP | ▲ Buy | Grant | 115 | $24K | 10/14/2024 | View on chart |
| INSP | ▲ Buy | Grant | 154 | $21K | 7/15/2024 | View on chart |
| INSP | ▲ Buy | Grant | 716 | $0 | 5/2/2024 | View on chart |
| INSP | ▲ Buy | Grant | 70 | $16K | 4/12/2024 | View on chart |
| TTC | ▲ Buy | Option Exercise | 5,192 | $160K | 3/15/2024 | View on chart |
| TTC | ▼ Sell | Open Market | 5,192 | $461K | 3/15/2024 | View on chart |
| INSP | ▲ Buy | Grant | 8 | $1K | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 87 | $16K | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 2 | $652 | 1/16/2024 | View on chart |
| TTC | ▲ Buy | Grant | 943 | $0 | 11/1/2023 | View on chart |
| INSP | ▲ Buy | Grant | 99 | $15K | 10/13/2023 | View on chart |
| INSP | ▲ Buy | Grant | 46 | $15K | 7/17/2023 | View on chart |
| INSP | ▲ Buy | Grant | 669 | $0 | 4/27/2023 | View on chart |
| INSP | ▲ Buy | Grant | 64 | $15K | 4/10/2023 | View on chart |
| TTC | ▲ Buy | Option Exercise | 5,104 | $149K | 3/22/2023 | View on chart |
| TTC | ▼ Sell | Open Market | 5,104 | $564K | 3/22/2023 | View on chart |
| INSP | ▲ Buy | Grant | 60 | $15K | 1/10/2023 | View on chart |
| TTC | ▲ Buy | Grant | 939 | $0 | 11/1/2022 | View on chart |
| INSP | ▲ Buy | Grant | 88 | $15K | 10/11/2022 | View on chart |
| INSP | ▲ Buy | Grant | 77 | $15K | 7/11/2022 | View on chart |
| TTC | ▲ Buy | Option Exercise | 6,842 | $147K | 6/9/2022 | View on chart |
| TTC | ▼ Sell | Open Market | 6,842 | $570K | 6/9/2022 | View on chart |
| INSP | ▲ Buy | Grant | 59 | $15K | 4/8/2022 | View on chart |
| INSP | ▲ Buy | Grant | 65 | $15K | 1/10/2022 | View on chart |
| TTC | ▲ Buy | Grant | 717 | $0 | 11/1/2021 | View on chart |
| INSP | ▲ Buy | Grant | 64 | $15K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight
Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.